Insider Selling: Phreesia, Inc. (NYSE:PHR) CFO Sells 864 Shares of Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 864 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $21.03, for a total value of $18,169.92. Following the completion of the sale, the chief financial officer now directly owns 97,714 shares in the company, valued at approximately $2,054,925.42. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Balaji Gandhi also recently made the following trade(s):

• On Tuesday, September 10th, Balaji Gandhi sold 3,502 shares of Phreesia stock. The stock was sold at an average price of $23.25, for a total value of $81,421.50.

Phreesia Stock Down 2.9 %

Shares of NYSE:PHR opened at $19.81 on Friday. The firm has a market cap of $1.14 billion, a P/E ratio of -11.01 and a beta of 0.93. Phreesia, Inc. has a 12-month low of $12.05 and a 12-month high of $29.16. The business has a fifty day simple moving average of $23.30 and a 200 day simple moving average of $22.42. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 0.03.

Phreesia (NYSE:PHR) last issued its quarterly earnings results on Wednesday, September 4th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.37) by $0.06. The company had revenue of $102.12 million during the quarter, compared to analysts’ expectations of $101.76 million. Phreesia had a negative return on equity of 39.34% and a negative net margin of 25.73%. Analysts predict that Phreesia, Inc. will post -1.23 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Phreesia by 4.4% during the fourth quarter. Vanguard Group Inc. now owns 4,628,441 shares of the company’s stock worth $107,148,000 after buying an additional 194,035 shares during the period. Capital International Investors boosted its position in Phreesia by 221.1% during the first quarter. Capital International Investors now owns 2,593,063 shares of the company’s stock valued at $62,052,000 after acquiring an additional 1,785,463 shares during the last quarter. Champlain Investment Partners LLC acquired a new stake in Phreesia during the 1st quarter worth about $29,941,000. Blair William & Co. IL raised its position in shares of Phreesia by 42.6% in the 1st quarter. Blair William & Co. IL now owns 752,700 shares of the company’s stock worth $18,012,000 after acquiring an additional 224,950 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC lifted its stake in shares of Phreesia by 4.5% in the 1st quarter. Silvercrest Asset Management Group LLC now owns 447,638 shares of the company’s stock valued at $10,712,000 after purchasing an additional 19,454 shares during the period. Institutional investors and hedge funds own 92.10% of the company’s stock.

Analyst Upgrades and Downgrades

PHR has been the subject of several research analyst reports. JPMorgan Chase & Co. boosted their target price on Phreesia from $27.00 to $28.00 and gave the stock an “overweight” rating in a research note on Monday, September 9th. Canaccord Genuity Group reiterated a “buy” rating and set a $34.00 price objective on shares of Phreesia in a research report on Thursday, September 5th. Royal Bank of Canada restated a “sector perform” rating and issued a $23.00 target price on shares of Phreesia in a research report on Friday, September 27th. Robert W. Baird upped their price target on shares of Phreesia from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Friday, September 6th. Finally, JMP Securities reissued a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a report on Thursday, September 5th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.42.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.